

SHAL Technologies Inc.



Contact:
Rod Balhorn

Location:
Livermore, CA

Email:
rod@shaltech.com

Tel:
925-203-5690

Website:
<http://www.shaltech.com>



Company Profile

Industry Sector: Oncology pharmaceuticals

Company Overview: What SHAL Technologies brings to the drug development industry is a unique Selective High Affinity Ligand (SHAL) platform that can be used to develop more efficacious, less toxic and more cost effective therapeutics for advanced stages of cancer and other life-threatening diseases. Pre-clinical studies of SH7139, our most advanced drug for treating non-Hodgkin's lymphoma, have demonstrated remarkable success in animal models without toxicity and suggest SHALs have the potential to provide cures for advanced B-cell derived cancers rather than incremental increases in the delay of disease progression afforded by current therapies.

Target Market(s): Hospitals, cancer centers and clinics



Key Value Drivers

Technology: SH7139 and other targeted small molecule cancer therapeutics developed using our Selective High Affinity Ligand platform that function similar to both antibody drug conjugates and pro-drugs.

Competitive Advantage: Demonstrates unprecedented efficacy in mouse xenograft models (by injection and oral dosing), no evidence of systemic toxicity to date, targets unique receptor not targeted by other drugs, is expected to be effective in treating a broader range of NHL subtypes, is effective at 1/30th to 1/300th the dose of other drugs, and employs multiple mechanisms to selectively kill tumor cells making it difficult for tumors to become resistant.

Plan & Strategy: Complete pre-clinical testing and move SH7139 into Phase I trial (2017) using grants/investment funds, advance others in pipeline, and license to Pharma.



Management, Staff, Advisors

Leadership: Rod Balhorn, CEO; Monique Cosman Balhorn, COO; Hugh Bagatelle, CFO

Clinical Advisors: Steven Park, Lineberger Cancer Center, UNC; Joseph Tuscano, UC Davis Medical Center; Richard Baum, Zentralklinik Bad Berka, Germany; Lan Pham, MD Anderson Cancer Center, UT; Rob Rebhun, Center for Companion Animal Health, UC Davis.

Synthetic Chemistry: Saphon Hok

Toxicology: Vincent Murphy (Consultant)

Manufacturing: AmbioPharm Inc., North Augusta, SC



Product Pipeline

SH7139: First in class targeted small molecule therapeutic for treating B-cell lymphomas and other cancers expressing HLA-DR10.

SH7129: Companion diagnostics for use in pre-screening patients to identify those with lymphomas that should respond to SH7139 therapy.

SH8037: Targeted small molecule therapeutic for veterinary applications (B-cell lymphomas in pet dogs).

SH8041: SH7139 analog that may have applications for the treatment of HLA-DR linked autoimmune diseases (rheumatoid arthritis, multiple sclerosis).